CLINUVEL has launch a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease in fair-skinned patients.
Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing in Dusseldorf, Germany.
Malibu shines a light on CLINUVELs pioneering work in photomedicine
CLINUVEL Launches CYACÊLLE, Next Generation Solar Care
Global SCENESSE® demand drives increased CLINUVEL revenues, earnings
CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals
Clinuvel Pharmaceuticals has reported data from a Phase II CUV156 study of its melanocortin drug, afamelanotide, in xeroderma pigmentosum (XP) patients.
CLINUVEL Trial Results Show Drug Reduces DNA Damage
MELBOURNE, Australia, May 09, 2022 (GLOBE NEWSWIRE) -- A new potential therapy for the pigment loss disorder vitiligo will undergo further studies in North America this year. The drug afamelanotide...
LONDON, April 29, 2022 (GLOBE NEWSWIRE) -- Â Â Â Dear shareholders, friends, Both from a professional viewpoint and as largest private holder, I have felt the urge to share my uncensored mind on...